
51 - 200 employees
Founded 2011
𧬠Biotechnology
π Pharmaceuticals
π° $54.9M Series C - Numab on 2025-01
Biotechnology β’ Pharmaceuticals
Numab Therapeutics AG is a Swiss biotechnology company based in Horgen that discovers and develops next-generation multispecific antibody-based therapeutics for immunology and immuno-oncology. Numab uses proprietary discovery and engineering platforms (Ξ»-Capβ’ and MATCHβ’) to design plug-and-play multispecific molecules intended to improve potency, stability, pharmacokinetics, duration of effect, and safety versus first-generation antibodies. The company advances an in-house pipeline and collaborates with pharmaceutical partners (e. g. , Boehringer Ingelheim, Kaken Pharmaceutical) to co-develop and license multispecific antibody candidates for diseases including inflammatory bowel disease and retinal and tumor indications.
π₯ 1 minute ago
Improve your chances of getting an interview by checking your resume score before you apply.

51 - 200 employees
Founded 2011
𧬠Biotechnology
π Pharmaceuticals
π° $54.9M Series C - Numab on 2025-01
Biotechnology β’ Pharmaceuticals
Numab Therapeutics AG is a Swiss biotechnology company based in Horgen that discovers and develops next-generation multispecific antibody-based therapeutics for immunology and immuno-oncology. Numab uses proprietary discovery and engineering platforms (Ξ»-Capβ’ and MATCHβ’) to design plug-and-play multispecific molecules intended to improve potency, stability, pharmacokinetics, duration of effect, and safety versus first-generation antibodies. The company advances an in-house pipeline and collaborates with pharmaceutical partners (e. g. , Boehringer Ingelheim, Kaken Pharmaceutical) to co-develop and license multispecific antibody candidates for diseases including inflammatory bowel disease and retinal and tumor indications.
β’ The Vice President, Medical will play a dual role spanning Clinical Development and Medical Affairs. β’ Internally, they will provide medical leadership for the ongoing development of Numab's IBD programme, contributing to clinical strategy, trial design, data interpretation, and development planning. β’ A key focus will be helping shape the design of early phase studies in patients and identifying innovative approaches that maximize the opportunity to demonstrate meaningful clinical differentiation in a competitive therapeutic landscape. β’ Externally, they will establish and maintain trusted relationships with leading experts in IBD and related fields, helping ensure that Numab's science, data, and therapeutic approach are understood within the broader context of disease biology and evolving treatment paradigms. β’ The individual will serve as a credible scientific ambassador for the company and play an important role in shaping external scientific dialogue surrounding both the programme and the future role of tri-specific antibodies in IBD.
β’ MD or equivalent medical qualification. β’ Significant experience within biotechnology or pharmaceutical drug development. β’ Deep expertise in inflammatory bowel disease, with an established reputation and network within the IBD community. β’ Experience spanning both Medical Affairs and Clinical Development. β’ Strong understanding of inflammatory pathways, disease pathophysiology, biologic therapies, and evolving treatment approaches in IBD. β’ Demonstrated experience contributing to clinical study design, development strategy, and interpretation of clinical data. β’ Proven ability to engage and influence scientific discussions with external experts through credible, evidence-based scientific exchange.
β’ Please note that applications that do not meet the requirements will not be considered.
Apply Nowπ July 20
VP of Commercial leading regional sales for Accuray's cancer treatment systems. Collaborating with marketing, service, and clinical teams to develop sales strategies and drive growth.
π¨π Switzerland β Remote
π° Post-IPO Debt on 2016-01
β° Full Time
π΄ Lead
π Vice President
π March 11
VP Platform responsible for technical and organizational scaling at Exoscale, a leading Swiss cloud provider. Leading a distributed team and mentoring managers to align business goals and platform roadmap.
π¨π Switzerland β Remote
π° Venture Round on 2015-02
β° Full Time
π΄ Lead
π Vice President